Tvardi Therapeutics Book Value Per Share Growth & History (TVRD)
Tvardi Therapeutics's book value per share was $2.23 for fiscal 2025.
View full Tvardi Therapeutics company overviewTvardi Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.23 | $37.63 | — |
| 2024 | 2024-12-31 | -$35.39 | $5.61 | — |
| 2023 | 2023-12-31 | -$41.01 | -$147.69 | — |
| 2022 | 2022-12-31 | $106.68 | -$47.09 | −30.62% |
| 2021 | 2021-12-31 | $153.77 | -$26.69 | −14.79% |
| 2020 | 2020-12-31 | $180.46 | $36.01 | +24.93% |
| 2019 | 2019-12-31 | $144.45 | $22.32 | +18.27% |
| 2018 | 2018-12-31 | $122.13 | $26.10 | +27.18% |
| 2017 | 2017-12-31 | $96.03 | $28.87 | +42.98% |
| 2016 | 2016-12-31 | $67.17 | -$72.14 | −51.79% |
| 2015 | 2015-12-31 | $139.31 | $57.41 | +70.11% |
| 2014 | 2014-12-31 | $81.89 | $537.68 | — |
| 2013 | 2013-12-31 | -$455.79 | $180.94 | — |
| 2012 | 2012-12-31 | -$636.73 | — | — |
Tvardi Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.89 | -$2.62 | −74.57% |
| Q1 2026 | 2026-03-31 | $1.55 | $67.55 | — |
| Q4 2025 | 2025-12-31 | $2.23 | $37.63 | — |
| Q3 2025 | 2025-09-30 | $2.97 | $54.71 | — |
| Q2 2025 | 2025-06-30 | $3.51 | $51.67 | — |
| Q1 2025 | 2025-03-31 | -$66.00 | -$22.25 | — |
| Q4 2024 | 2024-12-31 | -$35.39 | $5.61 | — |
| Q3 2024 | 2024-09-30 | -$51.73 | -$108.56 | — |
| Q2 2024 | 2024-06-30 | -$48.16 | -$120.98 | — |
| Q1 2024 | 2024-03-31 | -$43.75 | -$135.23 | — |
| Q4 2023 | 2023-12-31 | -$41.01 | -$147.69 | — |
| Q3 2023 | 2023-09-30 | $56.83 | -$67.49 | −54.29% |
| Q2 2023 | 2023-06-30 | $72.82 | -$64.75 | −47.07% |
| Q1 2023 | 2023-03-31 | $91.47 | -$46.19 | −33.55% |
| Q4 2022 | 2022-12-31 | $106.68 | -$47.09 | −30.62% |
| Q3 2022 | 2022-09-30 | $124.32 | -$24.93 | −16.70% |
| Q2 2022 | 2022-06-30 | $137.57 | -$9.26 | −6.31% |
| Q1 2022 | 2022-03-31 | $137.67 | -$28.84 | −17.32% |
| Q4 2021 | 2021-12-31 | $153.77 | -$26.69 | −14.79% |
| Q3 2021 | 2021-09-30 | $149.25 | $50.71 | +51.46% |
| Q2 2021 | 2021-06-30 | $146.82 | $38.13 | +35.08% |
| Q1 2021 | 2021-03-31 | $166.51 | $42.38 | +34.14% |
| Q4 2020 | 2020-12-31 | $180.46 | $36.01 | +24.93% |
| Q3 2020 | 2020-09-30 | $98.54 | -$65.55 | −39.95% |
| Q2 2020 | 2020-06-30 | $108.69 | $18.80 | +20.92% |
| Q1 2020 | 2020-03-31 | $124.13 | $19.53 | +18.68% |
| Q4 2019 | 2019-12-31 | $144.45 | $22.32 | +18.27% |
| Q3 2019 | 2019-09-30 | $164.09 | $26.88 | +19.59% |
| Q2 2019 | 2019-06-30 | $89.89 | $12.34 | +15.91% |
| Q1 2019 | 2019-03-31 | $104.59 | $24.90 | +31.24% |
| Q4 2018 | 2018-12-31 | $122.13 | $26.10 | +27.18% |
| Q3 2018 | 2018-09-30 | $137.21 | $27.39 | +24.94% |
| Q2 2018 | 2018-06-30 | $77.55 | -$43.67 | −36.02% |
| Q1 2018 | 2018-03-31 | $79.70 | $40.98 | +105.85% |
| Q4 2017 | 2017-12-31 | $96.03 | $28.87 | +42.98% |
| Q3 2017 | 2017-09-30 | $109.82 | $14.69 | +15.45% |
| Q2 2017 | 2017-06-30 | $121.22 | $11.80 | +10.79% |
| Q1 2017 | 2017-03-31 | $38.72 | -$87.04 | −69.21% |
| Q4 2016 | 2016-12-31 | $67.17 | -$72.14 | −51.79% |
| Q3 2016 | 2016-09-30 | $95.12 | -$56.01 | −37.06% |
| Q2 2016 | 2016-06-30 | $109.41 | $42.19 | +62.77% |
| Q1 2016 | 2016-03-31 | $125.76 | $50.66 | +67.46% |
| Q4 2015 | 2015-12-31 | $139.31 | $57.41 | +70.11% |
| Q3 2015 | 2015-09-30 | $151.13 | $63.33 | +72.12% |
| Q2 2015 | 2015-06-30 | $67.22 | -$31.08 | −31.62% |
| Q1 2015 | 2015-03-31 | $75.10 | -$28.46 | −27.48% |
| Q4 2014 | 2014-12-31 | $81.89 | $537.68 | — |
| Q3 2014 | 2014-09-30 | $87.80 | — | — |
| Q2 2014 | 2014-06-30 | $98.30 | — | — |
| Q1 2014 | 2014-03-31 | $103.56 | — | — |
| Q4 2013 | 2013-12-31 | -$455.79 | — | — |
Tvardi Therapeutics book value per share trends
Over the last five fiscal years, Tvardi Therapeutics's book value per share decreased from $180.46 to $2.23, a change of -$178.23. The latest reported quarter, Q2 2026, shows $0.89.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tvardi Therapeutics source filings ↗